PHARMNOVO
PharmNovo addresses the high unmet need of treatments for chronic pain, which affects up to 30% of the adult population in the USA & Europe.
PHARMNOVO
Social Links:
Industry:
Health Care Pharmaceutical
Founded:
2008-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.pharmnovo.com
Total Employee:
11+
Status:
Active
Contact:
+46 (0)705 44 32 50
Email Addresses:
[email protected]
Total Funding:
9.92 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Apache Euro Smart App Banner Embedly Nextcloud
Similar Organizations
Braeburn
Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder.
EnBiotix
EnBiotix advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections.
Zai Lab
Zai Lab brings transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sciety
Sciety investment in Series A - PharmNovo
Sciety
Sciety investment in Venture Round - PharmNovo
Karolinska
Karolinska investment in Venture Round - PharmNovo
Almi Invest
Almi Invest investment in Venture Round - PharmNovo
Polynom Investment
Polynom Investment investment in Venture Round - PharmNovo
Sciety
Sciety investment in Series A - PharmNovo
Official Site Inspections
http://www.pharmnovo.com Semrush global rank: 6.08 M Semrush visits lastest month: 1.34 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "PharmNovo"
PharmNovo - Crunchbase Company Profile & Funding
PharmNovo's goal is to develop novel Delta Opioid Receptor Agonists that are safe and effective for chronic pain treatment (DORAs). This is a very different …See details»
For investors | PharmNovo
The opportunity. PharmNovo is a pharmaceutical company at the clinical stage of developing a unique type of treatment for neuropathic pain, a condition currently lacking effective and safe …See details»
PharmNovo - Funding, Financials, Valuation & Investors
PharmNovo addresses the high unmet need of treatments for chronic pain, which affects up to 30% of the adult population in the USA & Europe. ... How much funding has this organization …See details»
Search for chronic pain treatment initiated 2008
Focusing on chronic pain. PharmNovo was founded in 2008 by the international medical researcher Bengt von Mentzer after 27 years as a drug discovery group leader for Astra Zeneca.. Finding a safe and effective way to help patients …See details»
PharmNovo 2025 Company Profile: Valuation, Funding …
PharmNovo General Information Description. Developer of nerve pain drugs and therapies intended to discover safe and effective drugs to make lives better. …See details»
About PharmNovo - pharmiweb.jobs
5 days ago PharmNovo AB is a Swedish clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack …See details»
PharmNovo - 2025 Company Profile, Funding & Competitors
Mar 13, 2025 PharmNovo. has raised a total funding of $20.9M over 4 rounds. Its first funding round was on Nov 04, 2020. What are the most recent funding rounds of PharmNovo? Its …See details»
Get in Touch - PharmNovo
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break-through potential in treatment of neuropathic pain. Being one …See details»
PharmNovo - Products, Competitors, Financials, Employees, …
PharmNovo receives positiv FDA feedback Photo: PharmNovo The company has received positive and constructive feedback for its lead drug product PN6047, a selective delta opioid …See details»
PharmNovo | LinkedIn
PharmNovo | 704 followers on LinkedIn. Innovation in pain relief | PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for …See details»
PharmNovo's Leadership Team Team - Team members and org …
Other teams at PharmNovo. View all +5. Board of Directors. 8 members. CEO and Executive Team. 2 members. The Org helps you hire great candidates. It takes less than ten minutes to …See details»
Karolinska Development's portfolio company PharmNovo receives …
Mar 12, 2025 PharmNovo’s most advanced drug candidate, PN6047, is a selective delta-opioid receptor agonist (DORA) being developed as a new treatment for complex pain conditions. …See details»
Anthony P D Ford | PharmNovo
Roles in PharmNovo: Business advisor and Director of the board. Born: 1965. Education: Ph.D. Trained in neuropharmacology and holds a Ph.D. from the University of Nottingham (UK). …See details»
Pharmnovo receives positive FDA feedback on PN6047, aims for …
Mar 12, 2025 Pharmnovo has received positive feedback from the FDA on its lead drug candidate PN6047. This is stated in a press release.Pharmnovo is a portfolio company of …See details»
Meet Jarkko Kalliomäki, Chief Medical Officer, PharmNovo
Oct 03, 2023: At the forefront of PharmNovo's journey towards pioneering solutions in pain relief stands Jarkko Kalliomäki, our esteemed Chief Medical Officer since September 2022. With his …See details»
PharmNovo announces positive Phase I results for neuropathic …
Mar 22, 2024 Swedish pharmaceutical company PharmNovo is proud to announce the positive final results from the Phase I trial of its neuropathic pain drug candidate, PN6047. This trial …See details»
Karolinska Development's portfolio company PharmNovo
Mar 12, 2025 PharmNovo’s most advanced drug candidate, PN6047, is a selective delta-opioid receptor agonist (DORA) being developed as a new treatment for complex pain conditions. …See details»
Karolinska Developments portföljbolag PharmNovo erhåller
STOCKHOLM, SVERIGE 12 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget PharmNovo erhöll positiv återkoppling rörande bolagets längst …See details»
Carl-Magnus Andersson | PharmNovo
PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with break …See details»
JPET approves PN6047 - PharmNovo
Oct 9, 2019 PharmNovo attended the LSX Nordic Congress in Copenhagen 8-9 October and Per von Mentzer, CEO presented PN6047, a unique first-in-class phase II ready asset with …See details»